Drugs / RGT-264
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05764915 | Feb 2023 → Feb 2024 | neoplasm | Regor Pharmaceuticals Inc. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RGT-264 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05764915 ↗ |
| Route | Oral | “RGT-264 phosphate tablets will be administered orally once daily (QD).” NCT05764915 ↗ |